Posts for Ticker ‘SCLN’

Top Day Trader Alerts (FOLD, BRCD, COF, FITB, SCLN, TRID, WFC)

These are this morning’s top day trader alerts and active trader alert stocks for Monday.  We have more details on volume and price analysis on each stock covered at VSInvestor.com:

Amicus Therapeutics (NASDAQ: FOLD) is hitting 52-week lows on its type 1 Gaucher disease treatment disappointment.

Brocade Communications Systems, Inc. (NASDAQ: BRCD) is trading up over 13% after the company has reportedly up for sale.

Capital One Financial Corp. (NYSE: COF) and Fifth Third Bancorp (NASDAQ: FITB) are both higher despite Goldman Sachs dropping FITB in favor of COF for its Conviction Buy List.

SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) is down 7% but not as bad as it could have been after dropping its Phase 2 trial evaluating RP101 for late-stage pancreatic cancer.

Trident Microsystems Inc. (NASDAQ: TRID) is surging on higher guidance and an NXP combination of their digital TV and Set-Top box businesses.

Wells Fargo & Co. (NYSE: WFC) is up over 4% on the Goldman Sachs upgrade.

You can join our open email distribution list which goes out several times per week for reminders of the top day trader alerts, analyst upgrades and downgrades, IPO’s, key secondary offerings, guru investor data on Buffett and others, mergers, and more.

JON C. OGG
October 5, 2009

Posted on: October 5, 2009 – 9:10 am in After-Hours Activity, Pre-Market Activity, Trading Alert, , , , , , ,

BioHealth Business Daily (AMGN, NVS, AMLN, LLY, ALKS, NVO, LLY, VICL, SCLN, ARNA)

These are some of the top stories affecting key drug and biotech stocks that are covered with more in-depth details and analysis this morning at BioHealthInvestor.com:

Amgen Inc’s (Nasdaq: AMGN)’s osteoporosis drug did so well in a head-to-head Phase III trial vs. the current standard drug from Novartis Inc. (NYSE:  NVS) that the Amgen’s drug may become the new standard for patients with breast cancer.

Amylin Pharmaceuticals Inc. (Nasdaq: AMLN), along with partners Eli Lilly & Co. (NYSE: LLY) and Alkermes Inc. (Nasdaq: ALKS), announced its new drug application for a once-weekly version of Byetta will be reviewed by the FDA, which may  help invigorate growth for the franchise.

Vical Inc. (Nasdaq: VICL) announced a positive four-month interim analysis for what is arguably its second-largest market opportunity, taking potentially another small step toward the goal of attracting a partner for its herpes vaccine program.

SciClone Pharmaceuticals Inc. (Nasdaq: SCLN) shares are down more than 7 percent on revenue and secondary offering fears. And Arena Pharmaceuticals Inc. (Nasdaq: ARNA) shares are falling after another dilutive offering.

Also, see our in-depth feature this week on five of the fastest-growing biotechs with improving analyst estimates: Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY), Amicus Therapeutics Inc. (Nasdaq: FOLD), Halozyme Therapeutics Inc. (Nasdaq: HALO), American Oriental Bioengineering Inc. (NYSE: AOB), and Stemcells Inc. (Nasdaq: STEM).

-The 24/7 Wall St. Team

Posted on: July 8, 2009 – 9:47 am in Biotech, Drug companies, FDA, Medical, , , , , , , , ,